DARZALEX FASPRO®
(daratumumab and hyaluronidase-fihj)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
Medical Information
Conversion Between Formulations
Last Updated: 07/08/2024
Summary
A summary of this response is provided as an interactive PDF (iPDF) that can be accessed by clicking the following link:
- DARZALEX®
(daratumumab) + DARZALEX FASPRO® (daratumumab and hyaluronidase) – Conversion Between Formulations - Minimum requirement to access interactive content: Adobe Acrobat Reader
- The executive summary infographic of the iPDF content is provided below
